Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Sym023 |
| Synonyms | |
| Therapy Description |
Sym023 is monoclonal antibody that targets T-cell immunoglobulin and mucin domain-3 protein (TIM-3, HAVCR2), potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5629). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Sym023 | Sym 023|Sym-023|S095018 | Immune Checkpoint Inhibitor 150 TIM-3 Antibody 9 | Sym023 is monoclonal antibody that targets T-cell immunoglobulin and mucin domain-3 protein (TIM-3, HAVCR2), potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5629). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03489343 | Phase I | Sym023 | Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas | Completed | USA | CAN | 0 |